The role of damage-associated molecular patterns (DAMPs) in human diseases part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine

Sultan Qaboos University Medical Journal

Volumn 15, Issue 2, 2015, Pages e157-e170

  Land, Walter G ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Adaptive immunity; Autoimmunity; Inflammation; Innate immunity; Pattern recognition; Receptors

Indexed keywords

EID: 84930060402     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Land WG. The role of damage associated molecular patterns in human diseases: Part I: Promoting inflammation and immunity. Sultan Qaboos Univ Med J 2015; 15:9-21.
2. Land WG. Emerging role of innate immunity in organ transplantation part II: Potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. Transplant Rev (Orlando) 2012; 26:73-87.doi: 10.1016/j.trre.2011.02.003.
3. Gallo PM, Gallucci S. The dendritic cell response to classic, emerging, and homeostatic danger signals: Implications for autoimmunity. Front Immunol 2013; 4:138. doi: 10.3389/fimmu.2013.00138.
4. Wenceslau CF, McCarthy CG, Szasz T, Spitler K, Goulopoulou S, Webb RC; Working Group on DAMPs in Cardiovascular Disease, et al. Mitochondrial damage-associated molecular patterns and vascular function. Eur Heart J2014351172-710.1093/eurheartj/ehu047
5. Zhang M, Carroll MC. Natural IgM-mediated innate autoimmunity: A new target for early intervention of ischemiareperfusion injury. Expert Opin Biol Ther 2007: 7:1575-1582. doi: 10.1517/14712598.7.10.1575.
6. Binder CJ. Naturally occurring IgM antibodies to oxidationspecific epitopes. Adv Exp Med Biol20127502-1310.1007/978-1-4614-3461-0_1
7. Uchida K. Natural antibodies as a sensor of electronegative damage-associated molecular patterns (DAMPs). Free Radic Biol Med201472 156-61110.1016/j.freeradbiomed.2014.03.016
8. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem2005747 39-8910.1146/ annurev.biochem.73.011303.074134
9. Wang S, Kaufman RJ. The impact of the unfolded protein response on human disease. J Cell Biol 2012 197 857-6710.1083/jcb.201110131
10. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-likereceptorsNat Immunol 2010;11:373-384.doi: 10.1038/ni.1863.
11. Lee EJ, Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: Potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics Inform 2013; 11:224-9.doi: 10.5808/ GI.2013.11.4.224.
12. Zhong Y, Kinio A, Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol 2013; 4:333. doi: 10.3389/fimmu.2013.00333.
13. Drummond RA, Brown GD. Signalling C-type lectins in antimicrobial immunity. PLoS Pathog 2013 9e1003417 10.1371/journal.ppat.1003417.
14. Jounai N, Kobiyama K, Takeshita F, Ishii KJ. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccinationFront Cell Infect Microbiol 2013 2:168 doi:10.3389/fcimb.2012.00168.
15. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids AnnuRevImmunol 2014;324 61-88.10.1146/annurev-immunol-032713-120156
16. Unterholzner L The interferon response to intracellular DNA: Why so many receptors? Immunobiology 2013; 218:1 312-321doi: 10.1016/j.imbio.2013.07.007.
17. Ratsimandresy RA, Dorfleutner A, Stehlik C. An update on PYRIN domain-containing pattern recognition receptors: From immunity to pathologyFront Immunol 2013; 4:doi: 10.3389/fimmu.2013.00440.
18. Wynn TA, Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012 1810 28-4010.1038/nm.2807.
19. Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury 2009; 40:912-918. doi: 10.1016/j. injury.2009.05.024.
20. Hirsiger S, Simmen HP, Werner CM, Wanner GA, Rittirsch D. Danger signals activating the immune response after trauma. Mediators Inflamm 2012 2012 315-94110.1155/2012/315941
21. Stoecklein VM, Osuka A, Lederer JA. Trauma equals dangerdamage control by the immune system. J Leukoc Biol 2012 925 39-51.10.1189/jlb.0212072
22. Straino S, Di Carlo A, Mangoni A, De Mori R, High-mobility group box 1 protein in human and murine skin: Involvement in woundhealingJ Invest Dermatol 2008;128:154-553.doi: 10.1038/sj.jid.5701212.
23. Yang S, Xu L, Yang T, Wang F. High-mobility group box-1 and its role in angiogenesis JLeukoc Biol 2014;955 63-74.10.1189/jlb.0713412
24. Zampell JC, Yan A, Avraham T, Andrade V, Malliaris S, Aschen S, et al. Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response tolymphedema Am J Physiol Cell Physiol 2011;300:1107-1121.doi: 10.1152/ajpcell.00378.2010.
25. Duffield JS, Lupher M, Thannickal VJ, Wynn TA. Host responses in tissue repair and fibrosis Annu Rev Pathol 2013; 82 41-76.10.1146/annurev-pathol-020712-163930
26. Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: Role of injury severity and tissue hypoperfusion. Crit Care 2009 13 R17410.1186/cc8152.
27. Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 2009; 32:17-22doi: 10.1097/SHK.0b013e3181997173..
28. Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin Chim Acta 2012; 413:1737-41doi: 10.1016/j.cca.2012.07.002.
29. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104-7.10.1038/nature08780
30. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, Vandenabeele P. Emerging role of damageassociated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32:157-64.doi: 10.1016/j.it.2011.01.005.
31. Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock 2010; 34:55-9.doi: 10.1097/SHK.0b013e3181cd8c08.
32. Walko TD 3rd, Bola RA, Hong JD, Au AK, Bell MJ, Kochanek PM, et al. Cerebrospinal fluid mitochondrial DNA: A novel DAMP in pediatric traumatic brain injury. Shock 2014; 41:499-503. doi: 10.1097/SHK.0000000000000160.
33. Simmons JD, Lee YL, Mulekar S, Kuck JL, Brevard SB, Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured humansubjects Ann Surg 2013 25 859-1610.1097/SLA.0b013e3182a4ea46
34. Huber-Lang M, Ignatius AThe role of complement in trauma and fracturehealingSemin Immunol 2013 25-73810.1016/j.smim.2013.05.006
35. Hansson GK, Hermansson AThe immune system inatherosclerosisNat Immunol 2011 12 204-1210.1038/ni.2001
36. Land WG Chronic allograft dysfunction: A model disorder of innateimmunity Biomed J 2013 362-092810.4103/23194170.117622
37. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosisAnnu Rev Pathol 2014;9:73-102.doi:10.1146/annurev-pathol-020712163936
38. Dobrin PB. Mechanical factors associated with the development of intimal and medial thickening in vein grafts subjected to arterial pressureA model of arteries exposed tohypertension. Hypertension 1995; 26:38-43doi: 10.1161/01.HYP.26.1.38.
39. Land WG. Interaction of Damage‑Associated Molecular Patterns and Pathogen‑Associated Molecular Patterns with Pattern Recognition Receptor-Bearing Vascular Cells and Myofibroblasts and its Consequences for the Development of Chronic Allograft Dysfunction. In: Land WG, Ed. Innate Alloimmunity. Part II. Innate immunity and rejection. Ankara, Lengerich: Başkent University-Pabst Science Publishers, 2011. Pp. 518-65.
40. Weismann D, The innate immune response to products of phospholipid peroxidation Biochim Biophys Acta; 1818:246-575
41. de Souza AW, Westra J, Limburg PC, Bijl M, HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11:909-917. 10.1016/j.autrev.2012.03.007.
42. Schiopu A, Cotoi OS. DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm 2013; 2013:828-854.
43. Ding Z, Liu S, Wang X, Dai Y, Khaidakov M, Deng X, et al. LOX-1, mtDNA damage and NLRP3 inflammasome activation in macrophages: Implications in atherogenesis. Cardiovasc Res 2014; 103:619-2810.1093/cvr/cvu114.
44. Zhou AX, Tabas I. The UPR in atherosclerosis Semin Immunopatho2013;35:321-32doi:10.1007/s00281-0130372x..
45. Menu P, Mayor A, Zhou R, Tardivel A, Ichijo H, Mori K, Tschopp J. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis 2012; 3:e261. doi: 10.1038/cddis.2011.132.
46. Chen YR, Cardiac mitochondria and reactive oxygen species generationCirc Res 2014 1145-2437doi: 10.1161/CIRCRESAHA.114.300559.
47. Ouyang YB, Stary CM, White RE, Giffard RG. The use of microRNAs to modulate redox and immune response to stroke. Antioxid Redox Signal 2015; 22:187-202. doi: 10.1089/ars.2013.5757.
48. Yellon DM, Hausenloy DJ. Myocardial reperfusion injuryN Engl J Med 2007 35 7112-713510.1056/NEJMra071667.
49. de Haan JJ, Smeets MB, Pasterkamp G, Arslan F. Danger signals in the initiation of the inflammatory response after myocardial infarction. Mediators Inflamm 2013; 2013:206-239doi: 10.1155/2013/206039.
50. Ding HS, Yang J, Chen P, Yang J, Bo SQ, Ding JW, et al. The HMGB1-TLR4 axis contributes to myocardial ischemia/ reperfusion injury via regulation of cardiomyocyte apoptosis. Gene 2013; 527:389-9310.1016/j.gene.2013.05.041.
51. Lu C, Ren D, Wang X, Ha T, Liu L, Lee EJ, et al. Toll-like receptor 3 plays a role in myocardial infarction and ischemia/ reperfusion injury. Biochim Biophys Acta 2014; 1842:22-311016/j.bbadis.2013.10.006.
52. Sandanger Ø, Ranheim T, Vinge LE, Bliksøen M, Alfsnes K, Finsen AV, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemiareperfusion injury. Cardiovasc Res 2013; 99:164-174. 10.1093/cvr/cvt091.
53. Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J20145510-551510.1536/ihj.13-388.
54. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouseProc Natl Acad Sci USA2011;108:197-2530doi: 10.1073/ pnas.1108586108..
55. Mezzaroma E, Marchetti C, Toldo S. Letter by Mezzaroma, et al regarding article, "NLRP3 inflammasome as a therapeutic target in myocardial infarction". Int Heart J 2014; 55:379doi: 10.1536/ihj.14-140..
56. Liaudet L, Rosenblatt-Velin N. Role of innate immunity in cardiac inflammation after myocardial infarction. Front Biosci (Schol Ed) 2013; 5:86-104doi: 10.2741/S359..
57. Cheng SC, Joosten LA, Netea MG. The interplay between central metabolism and innate immune responses. Cytokine Growth Factor Rev 2014; 25:707‒713. doi: 10.1016/j.cytogfr.2014.06.008.
58. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24:325-331. doi: 10.1152/physiol.00032.2009.
59. Eizirik DL, Miani M, Cardozo AK. Signalling danger: Endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 2013 56 23-44
60. Jin C, Innate sensors of pathogen and stress: Linking inflammation to obesity. J Allergy Clin Immunol 2013 13 228-7941016/j.jaci.2013.06.022.
61. Westwell-Roper C, Nackiewicz D, Dan MEhses JA. Toll-like receptors and NLRP3 as central regulators of pancreatic islet inflammation in type 2 diabetes. Immunol Cell Biol 2014 92 31-42310.1038/icb.2014.4..
62. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140:900- 17doi: 10.1016/j.cell.2010.02.034..
63. Oslowski CM, Urano F. The binary switch that controls the life and death decisions of ER stressed β cells. Curr Opin Cell Biol 2011 23 20-71510.1016/j.ceb.2010.11.005.
64. Lerner AG, Upton JP, Praveen PV, Ghosh R, Nakagawa Y, Igbaria A, et al. IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab 2012 162-506410.1016/j.cmet.2012.07.007.
65. Landau G, Kodali VK, Malhotra JD, Kaufman RJ. Detection of oxidative damage in response to protein misfolding in the endoplasmic reticulum. Methods Enzymol 2013 52-62315010.1016/B978-0-12-405883-5.00014-4.
66. Lu J, Holmgren A. The thioredoxin superfamily in oxidative protein folding. Antioxid Redox Signal 2014 214-577010.1089/ars.2014.5849.
67. Liu YP, Zeng L, Tian A, Bomkamp A, Rivera D, Endoplasmic reticulum stress regulates the innate immunity critical transcription factorIRF3J Immunol 2012; 189:46-309doi: 10.4049/jimmunol.1102737.
68. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62:194-20410.2337/db12-0420..
69. Kim S, Joe Y, Jeong SO, Zheng M, Back SH, Park SW, et al. Endoplasmic reticulum stress is sufficient for the induction of IL-1β production via activation of the NF-κB and inflammasome pathways. Innate Immun 2014; 20:799-815doi: 10.1177/1753425913508593..
70. Grant RW, Dixit VD. Mechanisms of disease: Inflammasome activation and the development of type 2 diabetes. Front Immunol 2013; 4:50doi: 10.3389/fimmu.2013.00050..
71. Fernandes-Alnemri T, Kang S, Anderson C, Sagara J, Fitzgerald KA, Alnemri ES. Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome. J Immunol 2013; 191:3995-9doi: 10.4049/jimmunol.1301681..
72. Masters SL. Specific inflammasomes in complex diseases. Clin Immunol 2013; 147:223-810.1016/j.clim.2012.12.006.
73. Shenderov K, Riteau N, Yip R, Mayer-Barber KD, Oland S, Hieny S, et al. Cutting edge: Endoplasmic reticulum stress licenses macrophages to produce mature IL-1β in response to TLR4 stimulation through a caspase-8- and TRIF-dependent pathway. J Immunol 2014; 192:2029-33doi: 10.4049/jimmunol.1302549..
74. Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, et al. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab 2012; 15:518-33doi: 10.1016/j.cmet.2012.01.023..
75. Oslowski CM, Hara T, O'Sullivan-Murphy B, Kanekura K, Lu S, Hara M, et al. Thioredoxin- interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab 2012; 16:265-273. doi: 10.1016/j.cmet.2012.07.005.
76. Anthony TG, Wek RC. TXNIP switches tracks toward a terminal UPR. Cell Metab 2012 16 13-5710.1016/j.cmet.2012.07.012.
77. Martinon F, Glimcher LH. Regulation of innate immunity by signaling pathways emerging from the endoplasmic reticulum. Curr Opin Immunol 2011; 23:35-40. doi: 10.1016/j.coi.2010.10.016.
78. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011 13 184-90101038/ncb0311-184.
79. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003 44 96010.1038/nrn1007.
80. Guillot-Sestier MV, Town T. Innate immunity in Alzheimer's disease: A complex affair. CNS Neurol Disord Drug Targets 2013; 12:593-607.
81. Swerdlow RH. Alzheimer's disease pathologic cascades: Who comes first, what drives what. Neurotox Res 2012 221-829410.1007/s12640-011-9272-9.
82. Cornejo VH, Hetz C. The unfolded protein response in Alzheimer's disease. Semin Immunopathol 2013 35 277-92101007/s00281-013-0373-9.
83. Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci 2014 15 233-24910.1038/nrn3689.
84. Li JQ, Yu JT, Jiang T, Tan L. Endoplasmic reticulum dysfunction in Alzheimer's disease. Mol Neurobiol 2015 513 839-5101007/s12035-014-8695-8.
85. Cao SS, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal 2014 21 396-413101089/ars.2014.5851..
86. Sutherland GT, Chami B, Youssef P, Witting PK. Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product? Redox Rep 2013 18 134-14110.1179/1351000213Y.0000000052.
87. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 2014; 1842:1240-1247. doi: 10.1016/j.bbadis.2013.10.015.
88. Chen Z, Zhong C. Oxidative stress in Alzheimer's disease. Neurosci Bull 2014 30 27-18110.1007/s12264-0131423-y.
89. Gibson GE, Chen HL, Xu H, Qiu L, Xu Z, Denton TT, Shi Q. Deficits in the mitochondrial enzyme α-ketoglutarate dehydrogenase lead to Alzheimer's disease-like calcium dysregulation. Neurobiol Aging 2012; 33:e13-e24. doi: 10.1016/j.neurobiolaging.2011.11.003.
90. Bradley-Whitman MA, Timmons MD, Beckett TL, Murphy MP, Lynn BC, Lovell MA. Nucleic acid oxidation: An early feature of Alzheimer's disease. J Neurochem 2014 128 294-30410.1111/jnc.12444.
91. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Scheper W. Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease. Neurodegener Dis 2012 10 21-25
92. Abisambra JF, Jinwal UK, Blair LJ, O'Leary JC 3rd, Li Q, Brady S, et al. Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci 2013; 33:94-98doi: 10.1523/JNEUROSCI.5397-12.2013.
93. Liu L, Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res Rev 2014 15-61510.1016/j.arr.2013.12.007.
94. Tan MS, Yu JT, Jiang T, Zhu X., Tan L. The NLRP3 inflammasome in Alzheimer's disease. Mol Neurobiol 2013 488-758210.1007/s12035-013-8475-x..
95. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008 98-576510.1038/ni.1636..
96. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013 49 36-74810.1038/nature11729..
97. Hamos JE, Oblas B, Pulaski-Salo D, Welch WJ, Bole DG, Drachman DA. Expression of heat shock proteins in Alzheimer's disease. Neurology 1991; 41:345-350. doi: 10.1212/WNL.41.3.345.
98. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: Amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009; 87:181-94.
99. Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, et al. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation. J Immunol 2012 18 810-9810710.4049/jimmunol.1101121..
100. Trotta T, Porro C, Calvello R, Panaro MA. Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol 2014 26 81-81210.1016/j.jneuroim.2014.01.014..
101. Shi JQ, Zhang CC, Sun XL, Cheng XX, Wang JB, Zhang YD, et al. Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-κB and NLRP3 inflammasome activation. CNS Neurosci Ther 2013 19 26-2810.1111/cns.12066..
102. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72doi: 10.1146/annurev-immunol-032712-100008..
103. Krysko O, Løve Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis 2013; 4:e631doi: 10.1038/cddis.2013.156..
104. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: What, when, and how? Biofactors 2013; 39:355-67doi: 10.1002/biof.1125..
105. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: Origins, plasticity and regulation. Cell Death Differ 2014; 21:26-38doi: 10.1038/cdd.2013.48..
106. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21:39-4910.1038/cdd.2013.84..
107. Dodd K, Nance S, Quezada M, Janke L, Morrison JB, Williams RT, Beere HM. Tumor- derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity. Oncogene 2015. 34:1312-22doi: 10.1038/onc.2014.63..
108. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8doi: 10.1038/nm.2028..
109. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15:1499-1509. doi:10.1038/cdd.2008.67.
110. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP, et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ 2012; 19:1880-91doi: 10.1038/cdd.2012.74..
111. Hou W, Zhang Q, Yan Z, Chen R, Zeh III HJ, Kang R, et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis 2013; 4:e966. doi: 10.1038/cddis.2013.493.
112. Carvalho FA, Aitken JD, Vijay-Kumar M, Gewirtz AT. Tolllike receptor-gut microbiota interactions: Perturb at your own risk! Annu Rev Physiol 2012; 74:177doi: 10.1146/annurevphysiol-020911-153330..
113. Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013; 13:321-35doi: 10.1038/nri3430..
114. Kamdar K, Nguyen V, DePaolo RW. Toll-like receptor signaling and regulation of intestinal immunity. Virulence 2013; 4:207-212doi: 10.4161/viru.23354..
115. Strober W. The impact of the gut microbiome on mucosal inflammation. Trends Immunol 2013; 34:423-430. doi: 10.1016/j.it.2013.07.001.
116. Collins SE, Mossman KL. Danger, diversity and priming in innate antiviral immunity. Cytokine Growth Factor Rev 2014 25 525-31101016/j.cytogfr.2014.07.002..
117. Roberts AP, Abaitua F, O'Hare P, McNab D, Rixon FJ, Pasdeloup D. Differing roles of inner tegument proteins pUL36 and pUL37 during entry of herpes simplex virus type 1. J Virol 2009 83 105-1610.1128/JVI.01032-08.
118. Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA, et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: Role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog 2014; 10:e1003848doi: 10.1371/journal.ppat.1003848..
119. Sursal T, Stearns-Kurosawa DJ, Itagaki K, Oh SY, Sun S, Kurosawa S, Hauser CJ. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Shock 2013 39 55-62101097/SHK.0b013e318276f4ca..
120. Yamanouchi S, Kudo D, Yamada M, Miyagawa N, Furukawa H, Kushimoto S. Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: Time course and the association with clinical status. J Crit Care 2013; 28:1027-1031. doi: 10.1016/j.jcrc.2013.05.006.